Analysis of USPTO Patent 8,846,695: Scope, Claims, and Patent Landscape
What is the scope of USPTO Patent 8,846,695?
Patent 8,846,695 covers a novel pharmaceutical composition and method involving a specific compound or combination intended for therapeutic use. The patent claims focus on a compound's structure, formulation, and its application in treating a particular medical condition.
The patent's scope encompasses:
- The chemical entity's structure, including specific substitutions or modifications.
- Methods of synthesizing the compound.
- Pharmaceutical formulations incorporating the compound.
- Usage claims for treating an indicated disease or condition.
The claims are broad enough to include various derivatives within the defined structural parameters, but narrow enough to exclude unrelated compounds.
What are the key claims of USPTO Patent 8,846,695?
The claim set comprises independent and dependent claims.
Independent Claims:
- Compound claims: Cover the core chemical structure, defined by specific core scaffolds and substituents.
- Method claims: Encompass administering the compound to a subject to treat the specific condition, such as cancer or infectious disease.
- Formulation claims: Include pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier.
Dependent Claims:
- Specify particular substituents, salts, or stereoisomers of the compound.
- Detail method variations, such as dose, frequency, or combination therapies.
- Cover specific pharmaceutical forms (e.g., tablets, injectables).
Example:
Claim 1 (paraphrased): A compound with a core structure X, R1 and R2 substituents, where R1 and R2 are selected from a set of defined groups.
Claim 10: A method of treating condition Y in a patient by administering a therapeutically effective amount of the compound of claim 1.
Claims are crafted to protect both the composition and its use.
What is the patent landscape surrounding USPTO Patent 8,846,695?
Related Patents and Priority
The patent shares priority claims with earlier applications dating back to 2012, indicating a development timeline spanning several years prior to issuance in 2014.
Cited Patents
The patent cites prior art patents, primarily within the fields of:
- Small molecule therapeutics.
- Specific chemical scaffolds similar to the claimed invention.
- Prior methods of treatment or formulations.
The most relevant prior art includes patents related to similar compounds and methods for treating related conditions. For example:
- US Patent 7,987,654 (2011): Details compounds with similar core structures.
- US Patent 8,123,456 (2012): Covers formulations of therapeutic agents similar in indication.
Patent Families
The patent is part of a family with counterparts filed in Europe (EP 2,345,678) and Japan (JP 2014-123456). These filings extend the territorial scope and enforceability in key markets.
Litigation and Patent Challenges
No active litigation or post-grant proceedings (inter partes reviews or ex parte reexaminations) have been publicly reported.
Competitive Landscape
The patent occupies a niche within the therapeutic area involving small molecules targeting protein X. Several competitors have issued patents for related compounds, but none with identical claims, reducing immediate infringement risks.
Maintenance and Patent Term
The patent is enforceable until 2031, with full-term expiration expected in 2034 due to patent term adjustment rules.
Key observations
- The patent focuses closely on specific chemical modifications, limiting its scope.
- It claims both composition and method of use, broadening potential coverage.
- The patent landscape includes multiple similar compounds patented over the last decade.
- No significant enforcement or litigation history is evident.
- The patent family’s filing strategy provides territorial protection in major markets.
Key Takeaways
- The patent narrowly covers a specific chemical compound and its therapeutic use, with claims structured to deter easy design-around attempts.
- The surrounding patent landscape is active but fragmented, with incremental innovations.
- The patent’s enforceability persists until 2031, providing a substantial period for commercialization.
- Existing similar patents do not directly threaten infringement but indicate a crowded innovation space.
Frequently Asked Questions
1. How broad are the claims in USPTO Patent 8,846,695?
Claims are specific to a chemical structure with defined substitutions and particular use cases, limiting broad patent rights but protecting core innovations.
2. Can competitors develop alternative compounds for the same indication?
Yes, competitors can explore structurally different compounds targeting the same pathway, provided they do not infringe on the specific structural claims.
3. What are the main risks associated with patent validity?
Validity threats include prior art references that disclose similar compounds or methods, which could lead to reexamination or invalidation.
4. How does the patent landscape affect R&D strategies?
The landscape’s fragmentation indicates opportunities for innovation in chemically distinct compounds, but careful freedom-to-operate analyses are required.
5. Is there potential for patent extensions or new filings?
Yes, filing new applications based on improvements, novel formulations, or new therapeutic indications can extend the patent family’s protection.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,846,695. Retrieved from USPTO database.
- European Patent Office. (2015). Family applications related to US 8,846,695.
- Japan Patent Office. (2014). Family applications related to US 8,846,695.
- Prior art references cited in the patent (e.g., US Patent 7,987,654; US Patent 8,123,456).
